Trans-Diethylstilbestrol
Trans-Diethylstilbestrol Uses, Dosage, Side Effects, Food Interaction and all others data.
A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed)
Trans-Diethylstilbestrol is a synthetic estrogen that was developed to supplement a woman's natural estrogen production. In 1971, the Food and Drug Administration (FDA) issued a Drug Bulletin advising physicians to stop prescribing DES to pregnant women because it was linked to a rare vaginal cancer in female offspring.
| Trade Name | Trans-Diethylstilbestrol |
| Availability | Discontinued |
| Generic | Diethylstilbestrol |
| Diethylstilbestrol Other Names | Diethylstilbestrol, Diéthylstilbestrol, Diethylstilbestrolum, Dietilestilbestrol, Stilboestrol, trans-Diethylstilbesterol, trans-Diethylstilbestrol, trans-Diethylstilboesterol |
| Related Drugs | estradiol, Premarin, Xtandi, Estrace, Casodex, Zytiga, Lynparza, Prempro, ethinyl estradiol |
| Type | |
| Formula | C18H20O2 |
| Weight | Average: 268.356 Monoisotopic: 268.146329884 |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Used in the treatment of prostate cancer. Previously used in the prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or premature delivery.
How Trans-Diethylstilbestrol works
Estrogens diffuse into their target cells and interact with a protein receptor, the estrogen receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. The effect of Estrogen binding their receptors causes downstream increases the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).
Toxicity
Symptoms of overdose include nausea and vomiting, and withdrawal bleeding may occur in females.
Trans-Diethylstilbestrol Cholesterol interaction
[Moderate] Although estrogens have generally favorable effects on plasma lipids, including increases in HDL and decreases in total cholesterol and LDL, they have also been associated with significant elevations in triglyceride levels, particularly when high dosages are used.
Severe hyperlipidemia is known to sometimes cause pancreatitis.
Patients with preexisting hyperlipidemia may require closer monitoring during estrogen therapy, and adjustments made accordingly in their lipid-lowering regimen.
Trans-Diethylstilbestrol Hypertension interaction
[Major] The risk of myocardial infarction and strokes, including those associated with oral contraceptive use and some estrogen use, is increased in patients with hypertension.
Moreover, estrogens (and progestogens) may elevate blood pressure and worsen the hypertension, thus compounding the risk.
Clinically significant blood pressure increases have been reported during estrogen therapy, particularly in patients receiving high dosages or treated with oral contraceptive combinations having high progestational activity.
These effects also increase with duration of therapy and patient age.
Therapy with estrogens should be administered cautiously in patients with preexisting hypertension.
Patients should be monitored for changes in cardiovascular status, and their antihypertensive regimen adjusted or estrogen therapy withdrawn as necessary.
In patients requiring contraception, alternative methods should be considered for those who are hypertensive, over age 35, and smoke.
Trans-Diethylstilbestrol Drug Interaction
Unknown: nifedipine, nifedipine, antihemophilic factor, antihemophilic factor, naproxen, naproxen, pemetrexed, pemetrexed, chloroquine, chloroquine, aspirin, aspirin, clofibrate, clofibrate, oxycodone, oxycodone, acetaminophen, acetaminophen, pantoprazole, pantoprazole
Trans-Diethylstilbestrol Disease Interaction
Major: abnormal vaginal bleeding, carcinomas (estrogenic), hypercalcemia in breast cancer, hypertension, thromboembolism/cardiovascular, hepatic neoplasmsModerate: angioedema, gallbladder disease, hypercalcemia, hyperlipidemia, liver disease, melasma, depression, fluid retention, glucose intolerance, retinal thrombosis, thyroid function tests
Innovators Monograph
You find simplified version here Trans-Diethylstilbestrol
